Categories: Health

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Taysha Gene Therapies, Inc.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted one new employee an option to purchase 90,000 shares of the Company’s common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.63 which is equal to the closing price of Taysha’s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee’s continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

GlobeNews Wire

Recent Posts

Aqua Labs Launches $20 Million Startup Support Program, Calling for Founders Worldwide

Dubai, Oct. 04, 2025 (GLOBE NEWSWIRE) -- Aqua Labs, an investment institution committed to advancing…

1 hour ago

Diginex Announces Completion of Acquisition of Matter DK ApS, Strengthening Diginexs AI-driven ESG Data and Analytics Leadership

October 03, 2025 16:05 ET  | Source: Diginex Limited LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE)…

1 hour ago

Solace Named to The Globe and Mail’s Seventh Annual Ranking of Canada’s Top Growing Companies

OTTAWA, ON, Sept. 30, 2025 /PRNewswire/ -- Solace, the leader in powering real-time, event-driven integration for…

1 hour ago

Trinasolar Vertex N Shield module wins comprehensive reliability award from TV Rheinland

CHANGZHOU, China, Sept. 30, 2025 /PRNewswire/ -- Trinasolar announced its Vertex N Shield module has…

1 hour ago

Envalior at K 2025 with material solutions to help customers reduce Time, Risk, Costs, and CO

At K 2025, Envalior will present its latest innovations in Sustainable & High-Performance Engineering Materials,…

4 hours ago

Using AI to Fight Overcrowded Animal Shelters – “CALL A PET” Launches on World Animal Day

BONN, Germany, Oct. 1, 2025 /PRNewswire/ -- On October 4th, World Animal Day, the German…

4 hours ago